(O-22) Intracavernosal botulinum toxin for erectile dysfunction: preliminary results from a double-blind, randomized controlled trial

Abstract Introduction/Objective Erectile dysfunction (ED) affects quality of life and has limited response to conventional treatments in ~30% of patients. Botulinum toxin (BT), a neuromodulator with smooth muscle relaxation effects, has shown potential in early studies. This study aims to assess the safety and efficacy of intracavernosal BT for ED in patients unresponsive to standard therapy. Materials and Methods This is a prospective, double-blind, randomized study comparing BT (100 U) vs. placebo (saline) injected into the penile shaft. Male participants aged ≥18 with IIEF-5 ≤ 21 and using standard ED treatments were eligible. Exclusion criteria included genitourinary neoplasms, radical prostatectomy, hypogonadism (testosterone